"RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity"

drug protocol number
CRFB002H2301E1
drug sponsor
Novartis
drug study
Ranibizumab
drug trial site
KFSH & RC-R
drug status
Completed
drug phase